Home > Compound List > Product Information
Simvastatin_Molecular_structure_CAS_79902-63-9)
Click picture or here to close

Simvastatin

Catalog No. DB00641 Name DrugBank
CAS Number 79902-63-9 Website http://www.ualberta.ca/
M. F. C25H38O5 Telephone (780) 492-3111
M. W. 418.56622 Fax (780) 492-1071
Purity Email david.wishart@ualberta.ca
Storage Chembase ID: 523

SYNONYMS

IUPAC name
(1S,3R,7S,8S,8aR)-8-{2-[(4R)-4-hydroxy-6-oxooxan-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbutanoate
IUPAC Traditional name
(1S,3R,7S,8S,8aR)-8-{2-[(4R)-4-hydroxy-6-oxooxan-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbutanoate
Brand Name
Sinvacor
Nivelipol
Rendapid
Simovil
Cholestat
Corolin
Denan
Labistatin
Medipo
Pantok
Sivastin
Synvinolin
Zocord
Coledis
Colemin
Lipex
Lodales
Vasotenal
Zocor
Synonyms
Simvastatinum [Latin]
Simvastatin [Usan:Ban:Inn]
Simvastatine [French]
Simvastatina [Spanish]

DATABASE IDS

CAS Number 79902-63-9

PROPERTIES

Hydrophobicity(logP) 4.7
Solubility 0.76 mg/L

DETAILS

Description (English)
Item Information
Drug Groups approved
Description A derivative of lovastatin and potent competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (hydroxymethylglutaryl COA reductases), which is the rate-limiting enzyme in cholesterol biosynthesis. It may also interfere with steroid hormone production. Due to the induction of hepatic LDL receptors, it increases breakdown of LDL cholesterol. [PubChem]
Indication For the treatment of hypercholesterolemia.
Pharmacology Simvastatin, the methylated form of lovastatin, is an oral antilipemic agent which inhibits HMG-CoA reductase. simvastatin is used in the treatment of primary hypercholesterolemia and is effective in reducing total and LDL-cholesterol as well as plasma triglycerides and apolipoprotein B.
Affected Organisms
Humans and other mammals
Biotransformation Hepatic, simvastatin is a substrate for CYP3A4.
Absorption Absorption of simvastatin, estimated relative to an intravenous reference dose, in each of two animal species tested, averaged about 85% of an oral dose. In animal studies, after oral dosing, simvastatin achieved substantially higher concentrations in the liver than in non-target tissues.
Half Life 3 hours
Protein Binding Both simvastatin and its b-hydroxyacid metabolite are highly bound (approximately 95%) to human plasma proteins.
Elimination Following an oral dose of 14C-labeled simvastatin in man, 13% of the dose was excreted in urine and 60% in feces.
References
Wolozin B, Wang SW, Li NC, Lee A, Lee TA, Kazis LE: Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease. BMC Med. 2007 Jul 19;5:20. [Pubmed]
External Links
Wikipedia
RxList
PDRhealth
Drugs.com

REFERENCES

  • Wolozin B, Wang SW, Li NC, Lee A, Lee TA, Kazis LE: Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease. BMC Med. 2007 Jul 19;5:20. Pubmed